Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 1 de 1
Filter
Add filters

Database
Language
Document Type
Year range
1.
Intern Med ; 59(18): 2327-2329, 2020 Sep 15.
Article in English | MEDLINE | ID: covidwho-792260

ABSTRACT

A 42-year-old man exhibiting hypoxia was diagnosed with coronavirus disease 2019. He had medical histories of type 2 diabetes, hyperlipidemia, hyperuricemia, and gout attack. He received favipiravir for compassionate use for 14 days. Subsequently, he showed increased uric acid levels and developed acute gouty arthritis. Favipiravir may induce not only hyperuricemia but also acute gouty arthritis. It should therefore be used with caution in patients with a history of gout and those with hyperuricemia, especially when used at a higher dose and for a longer duration than is typical.


Subject(s)
Amides/adverse effects , Antiviral Agents/adverse effects , Arthritis, Gouty/chemically induced , Betacoronavirus , Coronavirus Infections/drug therapy , Pneumonia, Viral/drug therapy , Pyrazines/adverse effects , Adult , Amides/therapeutic use , Antiviral Agents/therapeutic use , COVID-19 , Coronavirus Infections/complications , Humans , Hyperuricemia/complications , Lung/diagnostic imaging , Lung/pathology , Male , Pandemics , Pneumonia, Viral/complications , Pyrazines/therapeutic use , SARS-CoV-2 , Uric Acid/urine
SELECTION OF CITATIONS
SEARCH DETAIL